Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC
PR Newswire —
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC. Foresee will receive a 10 million USD upfront payment, potential milestones of up to 584.5 million USD, single-digit royalties and retains a 19% equity in Primevera, ensuring...